Small molecule · Inhibitor of cyclin D1 (CCND1) · developed by Traws Pharma
Briciclib is a phosphate ester prodrug of ON 013100, a benzyl styryl sulfone analog that is converted to its active form on hydrolysis. The active compound blocks cyclin D mRNA translation and reduces cyclin D protein, which may induce cell cycle arrest and apoptosis in cancer cells that overexpress cyclin D. It is studied in lymphoma, acute lymphocytic leukemia, and advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02168725 | Phase 1 | Neoplasms | Terminated | TRAW |
| NCT01049113 | Phase 1 | Lymphoma | Terminated | TRAW |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Lymphocytic LeukemiaAdvanced Solid TumorLymphomaNeoplasms
Updated Nov 1, 2026. Something wrong or missing? Report it on the TRAW page.
See TRAW's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TRAW catalysts and pipeline →